Related Experiment Video
Updated: Jun 30, 2026

Rat Model of Right-Sided Cardiac Remodeling and Arrhythmia Using Pulmonary Artery Banding
Published on: August 30, 2024
Latest Management of Cardiac Sarcoidosis: A Comprehensive Review
Dunia Alhareth1, Alaaeddine El Ghazawi1, Sara Ajami2
1Department of Internal Medicine, Cardiology Division, American University of Beirut Medical Center, Beirut, Lebanon, aubmc.org.lb.
Cardiac sarcoidosis (CS) management involves medications, devices, and lifestyle changes. Corticosteroids help inflammation, but steroid-sparing drugs are alternatives. Device interventions and ablation address arrhythmias and heart failure in CS.
Area of Science:
- Cardiology
- Immunology
- Internal Medicine
Background:
- Cardiac sarcoidosis (CS) is a rare, serious manifestation of sarcoidosis.
- CS presents heterogeneously, complicating diagnosis and management.
- Potential complications include conduction blocks, arrhythmias, and heart failure.
Purpose of the Study:
- To review management options for cardiac sarcoidosis.
- To discuss pharmacotherapy, device-based interventions, lifestyle modifications, and surgical options for CS.
- To highlight challenges in CS treatment, including interindividual variability and lack of strict guidelines.
Main Methods:
- Literature review of CS management strategies.
- Analysis of pharmacotherapy, including corticosteroids and steroid-sparing agents.
- Evaluation of device-based interventions (pacemakers, ICDs) and ablation techniques.
- Consideration of lifestyle modifications and surgical approaches.
Main Results:
- Corticosteroids show efficacy in reducing CS inflammation and improving cardiac parameters.
- Steroid-sparing medications are viable alternatives due to corticosteroid side effects.
- Device interventions and ablation are effective for managing arrhythmias and heart failure in CS patients.
- Lifestyle modifications are important adjunctive treatments.
Conclusions:
- Cardiac sarcoidosis requires a multifaceted management approach.
- Treatment strategies must balance efficacy with potential side effects and patient variability.
- Further research is needed to establish standardized guidelines for CS management.
Related Concept Videos
Cardiomyopathy V: Interprofessional Care
Myocarditis III: Medical Management
Cardiomyopathy IV: Restrictive Cardiomyopathy
Cardiomyopathy VI: Nursing Management
Pericarditis III: Medical Management
Cardiomyopathy III: Hypertrophic Cardiomyopathy